Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations.

Citation data:

Transfusion, ISSN: 1537-2995, Vol: 57, Issue: 6, Page: 1555-1565

Publication Year:
2017
Usage 47
Abstract Views 47
Captures 10
Exports-Saves 7
Readers 3
PMID:
28453219
DOI:
10.1111/trf.14112
Author(s):
Worsham, D Nicole, Reems, Jo-Anna, Szczepiorkowski, Zbigniew M, McKenna, David H, Leemhuis, Thomas, Mathew, Aby J, Cancelas, Jose A, Biomedical Excellence for Safer Transfusion (BEST) Collaborative Group
Publisher(s):
Wiley-Blackwell
Tags:
Medicine, Immunology and Microbiology
article description
Cryopreserved donor lymphocyte infusion (DLI) products are manufactured and administered to treat relapse after allogeneic hematopoietic stem cell transplantation. Reported clinical responses to DLIs vary broadly, even within the same group of patients. While there is an implicit recognition of the fact that different manufacturing protocols may have specific effects on different cell types, cryopreservation protocols are frequently derived from our experience in the cryopreservation of stem cell products and do not account for the heterogeneous functional nature of DLI T-cell populations. Here, we report the results of a prospective, multicenter trial on the effect of four different cryopreservation solutions that were used to freeze DLIs compared to control DLIs that were refrigerated overnight.

This article has 0 Wikipedia mention.